Fact sheet - Articles - Page 33

Fact Sheet

Relapse Prevention Strategies

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Most patients are not able to achieve sobriety from opioids in their first attempt.

Fact Sheet

How to Educate Your Patients About Overdose Prevention

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Drug overdose deaths, the vast majority of which involve opioids, continue to rise in the US.

Fact Sheet

Harm Reduction and Opioid Use Disorder

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Harm reduction refers to a set of strategies aimed at decreasing the negative effects of drug use and other potentially harmful behaviors.

Fact Sheet

Buprenorphine Microinduction

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

The standard method of starting a patient on buprenorphine involves having the patient stop all opioids hours to days before the induction.

Fact Sheet

Buprenorphine Monotherapy (Subutex, others)

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Buprenorphine (Subutex, available now only as generic) is the active ingredient in Suboxone (buprenorphine/naloxone) and is responsible for the effectiveness of the combination medication in opioid use disorder (OUD).

Fact Sheet

Buprenorphine Extended-Release Injection Monotherapy (Brixadi, Sublocade)

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Extended-release injectable formulations of buprenorphine allow patients to receive doses weekly, monthly, or every eight weeks for patients maintained on a low dose—which improves medication adherence.

Clinical Guidance

Medication Interactions

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Opioid use disorder (OUD) is highly comorbid with medical illness and other psychiatric conditions.

Clinical Guidance

Neonatal Opioid Withdrawal Syndrome: Recognition and Management

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Neonatal opioid withdrawal syndrome (NOWS), sometimes used interchangeably with the term neonatal abstinence syndrome (NAS), results from prenatal opioid exposure.

Clinical Guidance

Managing Opioid Use Disorder in Pregnant People

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Rates of opioid use disorder (OUD) and overdose deaths during pregnancy have skyrocketed in recent years.

Clinical Guidance

Levels of Care for Opioid Use Disorder Services

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

This fact sheet offers insights into various services for opioid use disorder (OUD), highlighting their definitions, typical durations, and referral considerations to optimize patient care.